Abstract
Forty patients with end-stage carcinoma of the head and neck were admitted to a randomized double blind trial with cisplatinum in one arm and cisplatinum + nifedipine in the other. Nifedipine, a calcium channel blocking drug, inhibits the effect of acquired multidrug resistance in animal models. In the present study the addition of this agent had no effect on either response rate or survival in end-stage carcinoma of the head and neck. It is concluded that adding nifedipine to cisplatinum serves no useful purpose in the treatment of end-stage carcinoma of the head and neck.
Publication types
-
Clinical Trial
-
Clinical Trial, Phase II
-
Comparative Study
-
Randomized Controlled Trial
MeSH terms
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
-
Carcinoma, Squamous Cell / drug therapy*
-
Carcinoma, Squamous Cell / mortality
-
Carcinoma, Squamous Cell / pathology
-
Cisplatin / administration & dosage
-
Cisplatin / therapeutic use*
-
Double-Blind Method
-
Female
-
Head and Neck Neoplasms / drug therapy*
-
Head and Neck Neoplasms / mortality
-
Head and Neck Neoplasms / pathology
-
Humans
-
Male
-
Middle Aged
-
Neoplasm Staging
-
Nifedipine / administration & dosage
-
Survival Rate